MMP-9 affects gene expression in chronic lymphocytic leukemia revealing CD99 as an MMP-9 target and a novel partner in malignant cell migration/arrest

Abstract

We previously showed that MMP-9 contributes to CLL pathology by regulating cell survival and migration and that, when present at high levels, MMP-9 induces cell arrest. To further explore the latter function, we studied whether MMP-9 influences the gene-expression profile in CLL. Microarray analyses rendered 131 differentially expressed genes in MEC-1 cells stably transfected with MMP-9 (MMP-9-cells) versus cells transfected with empty vector (Mock-cells). Ten out of twelve selected genes were also differentially expressed in MEC-1 cells expressing the catalytically inactive MMP-9MutE mutant (MMP-9MutE-cells). Incubation of primary CLL cells with MMP-9 or MMP-9MutE also regulated gene and protein expression, including CD99, CD226, CD52, and CD274. Because CD99 is involved in leukocyte transendothelial migration, we selected CD99 for functional and mechanistic studies. The link between MMP-9 and CD99 was reinforced with MMP-9 gene silencing studies, which resulted in CD99 upregulation. CD99 gene silencing significantly reduced CLL cell adhesion, chemotaxis and transendothelial migration, while CD99 overexpression increased cell migration. Mechanistic analyses indicated that MMP-9 downregulated CD99 via binding to α4β1 integrin and subsequent inactivation of the Sp1 transcription factor. This MMP-9-induced mechanism is active in CLL lymphoid tissues, since CD99 expression and Sp1 phosphorylation was lower in bone marrow-derived CLL cells than in their peripheral blood counterparts. Our study establishes a new gene regulatory function for MMP-9 in CLL. It also identifies CD99 as an MMP-9 target and a novel contributor to CLL cell adhesion, migration and arrest. CD99 thus constitutes a new therapeutic target in CLL, complementary to MMP-9.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

References

  1. 1.

    Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010;10:37–50.

    CAS  Article  Google Scholar 

  2. 2.

    Ten Hacken E, Burger JA. Microenvironment interactions and B-cell receptor signaling in Chronic LymphocyticLeukemia: Implications for disease pathogenesis and treatment. Biochim Biophys Acta. 2016;1863:401–13.

    Article  Google Scholar 

  3. 3.

    Davids MS, Burger JA. Cell Trafficking in chronic lymphocytic leukemia. Open J Hematol. 2012;3:3.

    Article  Google Scholar 

  4. 4.

    Bauvois B, Dumont J, Mathiot C, Kolb JP. Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons. Leukemia. 2002;16:791–8.

    CAS  Article  Google Scholar 

  5. 5.

    Kamiguti AS, Lee ES, Till KJ, Harris RJ, Glenn MA, Lin K, et al. The role of matrix metalloproteinase 9 in the pathogenesis of chronic lymphocytic leukaemia. Br J Haematol. 2004;125:128–40.

    CAS  Article  Google Scholar 

  6. 6.

    Redondo-Muñoz J, Escobar-Díaz E, Samaniego R, Terol MJ, García-Marco JA, García-Pardo A. MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood. 2006;108:3143–51.

    Article  Google Scholar 

  7. 7.

    Redondo-Muñoz J, Ugarte-Berzal E, García-Marco JA, del Cerro MH, Van den Steen PE, Opdenakker G, et al. α4β1 integrin and 190 kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood. 2008;112:169–78.

    Article  Google Scholar 

  8. 8.

    Redondo-Muñoz J, Ugarte-Berzal E, Terol MJ, Van den Steen PE, Hernández del Cerro M, Roderfeld M, et al. Matrix metalloproteinase-9 (MMP-9) promotes chronic lymphocytic leukemia B-cell survival through its hemopexin domain. Cancer Cell. 2010;17:160–72.

    Article  Google Scholar 

  9. 9.

    Amigo-Jiménez I, Bailón E, Ugarte-Berzal E, Aguilera-Montilla N, García-Marco JA, García-Pardo A. Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide. Plos One. 2014;9:e99993

    Article  Google Scholar 

  10. 10.

    Bailón E, Ugarte-Berzal E, Amigo-Jiménez I, Van den Steen P, Opdenakker G, García-Marco JA, et al. Overexpression of progelatinase B/proMMP-9 affects migration regulatory pathways and impairs chronic lymphocytic leukemia cell homing to bone marrow and spleen. J Leuk Biol. 2014;96:185–99.

    Article  Google Scholar 

  11. 11.

    Vandooren J, Van den Steen PE, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol. 2013;48:222–72.

    CAS  Article  Google Scholar 

  12. 12.

    Redondo-Muñoz J, Terol MJ, García-Marco JA, García-Pardo A. Matrix metalloproteinase-9 is up-regulated by CCL21/CCR7 interaction via extracellular signal-regulated kinase-1/2 signaling and is involved in CCL21-driven B-cell chronic lymphocytic leukemia cell invasion and migration. Blood. 2008;111:383–6.

    Article  Google Scholar 

  13. 13.

    Van den Steen PE, Van Aelst I, Hvidberg V, Piccard H, Fiten P, Jacobsen C, et al. The hemopexin and O-glycosylated domains tune gelatinase B/MMP-9 bioavailability via inhibition and binding to cargo receptors. J Biol Chem. 2006;281:18626–37.

    Article  Google Scholar 

  14. 14.

    Bailón E, Aguilera-Montilla N, Gutiérrez-González A, Ugarte-Berzal E, Van den Steen PE, Opdenakker G, et al. A catalytically inactive gelatinase B/MMP-9 mutant impairs homing of chronic lymphocytic leukemia cells by altering migration regulatory pathways. Biochem Biophys Res Commun. 2018;495:124–30.

    Article  Google Scholar 

  15. 15.

    Garcia-Pardo A, Opdenakker G. Nonproteolytic functions of matrix metalloproteinases in pathology and insights for the development of novel therapeutic inhibitors. Met Med. 2015;2:19–28.

    Google Scholar 

  16. 16.

    Sakamoto T, Seiki M. Cytoplasmic tail of MT1-MMP regulates macrophage motility independently from its protease activity. Genes Cells. 2009;14:617–26.

    CAS  Article  Google Scholar 

  17. 17.

    Gonzalo P, Guadamillas MC, Hernández-Riquer MV, Pollán A, Grande-García A, Bartolomé RA, et al. MT1-MMP is required for myeloid cell fusion via regulation of Rac1 signaling. Dev Cell. 2010;18:77–89.

    CAS  Article  Google Scholar 

  18. 18.

    Marchant DJ, Bellac CL, Moraes TJ, Wadsworth SJ, Dufour A, Butler GS, et al. A new transcriptional role for matrix metalloproteinase-12 in antiviral immunity. Nat Med. 2014;20:493–502.

    CAS  Article  Google Scholar 

  19. 19.

    Parry HM, Stevens T, Oldreive C, Zadran B, McSkeane T, Rudzki Z, et al. NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma. Oncotarget. 2016;7:68513–26.

    Article  Google Scholar 

  20. 20.

    McClanahan F, Hanna B, Miller S, Clear AJ, Lichter P, Gribben JG, et al. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. Blood. 2015;126:203–11.

    CAS  Article  Google Scholar 

  21. 21.

    Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;126:573–81.

    CAS  Article  Google Scholar 

  22. 22.

    Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017;92:946–65.

    CAS  Article  Google Scholar 

  23. 23.

    Ganghammer S, Gutjahr J, Hutterer E, Krenn PW, Pucher S, Zelle-Rieser C, et al. Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors. Haematologica. 2016;101:e99–102.

    CAS  Article  Google Scholar 

  24. 24.

    Vestweber D. How leukocytes cross the vascular endothelium. Nat Rev Immunol. 2015;15:692–704.

    CAS  Article  Google Scholar 

  25. 25.

    Muller WA. Transendothelial migration: unifying principles from the endothelial perspective. Immunol Rev. 2016;273:61–75.

    CAS  Article  Google Scholar 

  26. 26.

    Pasello M, Manara MC, Scotlandi K. CD99 at the crossroads of physiology and pathology. J Cell Commun Signal. 2018;12:55–68.

    Article  Google Scholar 

  27. 27.

    Hahn JH, Kim MK, Choi EY, Kim SH, Sohn HW, Ham DI, et al. CD99 (MIC2) regulates the LFA-1/ICAM-1-mediated adhesion of lymphocytes, and its gene encodes both positive and negative regulators of cellular adhesion. J Immunol. 1997;159:2250–8.

    CAS  PubMed  Google Scholar 

  28. 28.

    Bernard G, Raimondi V, Alberti I, Pourtein M, Widjenes J, Ticchioni M, et al. CD99 (E2) up-regulates α4β1-dependent T cell adhesion to inflamed vascular endothelium under flow conditions. Eur J Immunol. 2000;30:3061–5.

    CAS  Article  Google Scholar 

  29. 29.

    Lee I, Kim MK, Choi EY, Mehl A, Jung KC, Gil MC, et al. CD99 expression is positively regulated by Sp1 and is negatively regulated by Epstein-Barr virus latent membrane protein 1 through nuclear factor-κB. Blood. 2001;97:3596–604.

    CAS  Article  Google Scholar 

  30. 30.

    Lee JH, Kim SH, Wang LH, Choi YL, Kim YC, Kim JH, et al. Clinical significance of CD99 down-regulation in gastric adenocarcinoma. Clin Cancer Res. 2007;13:2584–91.

    CAS  Article  Google Scholar 

  31. 31.

    Opdenakker G, Van den Steen PE, Van Damme J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol. 2001;22:571–9.

    CAS  Article  Google Scholar 

  32. 32.

    Creighton C, Hanash S. Expression of matrix metalloproteinase 9 (MMP-9/gelatinase B) in adenocarcinomas strongly correlated with expression of immune response genes. Silico Biol. 2003;3:301–11.

    CAS  Google Scholar 

  33. 33.

    Prudova A, auf dem Keller U, Butler GS, Overall CM. Multiplex N-terminome analysis of MMP-2 and MMP-9 substrate degradomes by iTRAQ-TAILS quantitative proteomics. Mol Cell Proteom. 2010;9:894–911.

    CAS  Article  Google Scholar 

  34. 34.

    Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol. 2012;30:1647–55.

    CAS  Article  Google Scholar 

  35. 35.

    Manara MC, Pasello M, Scotlandi K. CD99: a cell surface protein with an oncojanus role in tumors. Genes. 2018;9:159.

    Article  Google Scholar 

  36. 36.

    Alberti I, Bernard G, Rouquette-Jazdanian AK, Pelassy C, Pourtein M, Aussel C, et al. CD99 isoforms expression dictates T cell functional outcomes. FASEB J. 2002;16:1946–8.

    Article  Google Scholar 

  37. 37.

    Scotlandi K, Zuntini M, Manara MC, Sciandra M, Rocchi A, Benini S, et al. CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity. Oncogene. 2007;26:6604–18.

    CAS  Article  Google Scholar 

  38. 38.

    Zucchini C, Manara MC, Pinca RS, De Sanctis P, Guerzoni C, Sciandra M, et al. CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity. Oncogene. 2014;33:1912–21.

    CAS  Article  Google Scholar 

  39. 39.

    Schenkel AR, Mamdouh Z, Chen X, Liebman RM, Muller WA. CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat Immunol. 2002;3:143–50.

    CAS  Article  Google Scholar 

  40. 40.

    Imbert AM, Belaaloui G, Bardin F, Tonnelle C, Lopez M, Chabannon C. CD99 expressed on human mobilized peripheral blood CD34+cells is involved in transendothelial migration. Blood. 2006;108:2578–86.

    CAS  Article  Google Scholar 

  41. 41.

    Seol HJ, Chang JH, Yamamoto J, Romagnuolo R, Suh Y, Weeks A, et al. Overexpression of CD99 increases the migration and invasiveness of human malignant glioma cells. Genes Cancer. 2012;3:535–49.

    CAS  Article  Google Scholar 

  42. 42.

    Goswami D, März S, Li YT, Artz A, Schäfer K, Seelige R, et al. Endothelial CD99 supports arrest of mouse neutrophils in venules and binds to neutrophil PILRs. Blood. 2017;129:1811–22.

    CAS  Article  Google Scholar 

  43. 43.

    Coustan-Smith E, Song G, Clark C, Key L, Liu P, Mehrpooya M, et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2011;117:6267–76.

    CAS  Article  Google Scholar 

  44. 44.

    Tan NY, Khachigian LM. Sp1 phosphorylation and its regulation of gene transcription. Mol Cell Biol. 2009;29:2483–8.

    CAS  Article  Google Scholar 

  45. 45.

    Beishline K, Azizkhan-Clifford J. Sp1 and the “hallmarks of cancer”. FEBS J. 2015;282:224–58.

    CAS  Article  Google Scholar 

  46. 46.

    Dal BoM, Bulian P, Bomben R, Zucchetto A, Rossi FM, Pozzo F, et al. CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. Leukemia. 2016;30:2011–8.

    Article  Google Scholar 

  47. 47.

    Brachtl G, Piñón Hofbauer J, Greil R, Hartmann TN. The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia. Ann Hematol. 2014;93:361–74.

    CAS  Article  Google Scholar 

  48. 48.

    Herishanu Y, Pérez-Galán P, Liu D, Biancotto A, Pittaluga S, Vire B, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117:563–74.

    CAS  Article  Google Scholar 

  49. 49.

    Mittal AK, Chaturvedi NK, Rai KJ, Gilling-Cutucache CE, Nordgren TM, Moragues M, et al. Chronic lymphocytic leukemia cells in a lymph node microenvironment depict molecular signature associated with an aggressive disease. Mol Med. 2014;20:290–301.

    Article  Google Scholar 

Download references

Acknowledgments

The authors thank Dr. Dolors Colomer for some of the paired CLL samples; Dr. Miguel A. Vega for expert help and advice with the microarray data analyses; Dr. Pedro Lastres for help with the flow cytometry analyses; and Guillermo Padilla for expert help with bioinformatics analyses.

Funding

This work was supported by Grant SAF2015-69180R and Red Temática de Investigación Cooperativa en Cáncer Grant RD12/0036/0061 from the Ministry of Economy and Competitivity (Spain) (to AGP); S2010/BMD-2314 (to AGP) from the Comunidad de Madrid/European Union; and by the Concerted Research Actions (KU Leuven C1 Grant C16/17/010) and the Research Foundation of Flanders (FWO-Vlaanderen, to EUB, PEVdS, and GO).

Author contributions

NAM and EB performed most of the research, designed experiments, and analyzed data; RUC performed research and analyzed data; AS, AGG, and CPS performed and analyzed some experiments; EUB designed and prepared cell transfectants and analyzed data; GO and PEVdS prepared and characterized the recombinant MMP-9 variants and critically reviewed the manuscript; JAGM contributed patient samples, with clinical, biological, and cytogenetic data; AGP designed and supervised research, had full access to the data, and wrote the paper. All authors reviewed and approved the final version of the manuscript.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Angeles García-Pardo.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Aguilera-Montilla, N., Bailón, E., Uceda-Castro, R. et al. MMP-9 affects gene expression in chronic lymphocytic leukemia revealing CD99 as an MMP-9 target and a novel partner in malignant cell migration/arrest. Oncogene 38, 4605–4619 (2019). https://doi.org/10.1038/s41388-019-0744-3

Download citation

Further reading